Biogen asks why Ireland won’t fund new spinal muscular atrophy drug

Biogen asks why Ireland won’t fund new spinal muscular atrophy drug

Biogen is also urgently calling on the HSE to reform the appraisal process for orphan medicines to treat rare diseases, arguing that there is a need for a greater degree of flexibility for these assessments

Biogen Ireland has called on Minister for Health Simon Harris to explain why Ireland joined an EU pharma partnership yet remains the only country in the partnership refusing to fund Biogen’s drug.

Please Subscribe or Log in to continue reading

Subscribe Login

Independent journalism every day

With digital access you can read The Business Post whenever, wherever, and however you want.

  • Unlimited access to all sections of The Business Post on desktop, tablet and mobile.
  • Breaking news, comment and analysis from the best Business Post writers seven days a week.
  • Live blogs of major news events
  • Videos and podcasts from some of the industry's most respected journalists such as Tom Lyons, Susan Mitchell and Ian Guider
  • Access to The Business Post's extensive archive​

Related Articles

More from The Business Post